Shares in Novo Nordisk fell as much as 15 per cent after the US Food and Drug Administration withheld approval for its new insulin treatment pending further tests. With a quick approval previously priced into its stock, the decision came as a shock to the company. Lex's Julia Grindell and Vincent Boland consider whether the group's shares are now fairly priced, and the impact of the decision on this year's earnings.<br /><br />Related Articles:<br />http://www.ft.com/intl/cms/s/0/4e55f55a-7422-11e2-a27c-00144feabdc0.html<br />http://www.ft.com/intl/cms/s/3/5fd083ca-7456-11e2-80a7-00144feabdc0.html<br /><br />For more video content from the Financial Times, visit http://www.FT.com/video
